LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Trinity Biotech plc (“Trinity” or the “Company”) (Nasdaq: TRIB) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at firstname.lastname@example.org.
The investigation concerns Trinity’s October 4, 2016 announcement that it will withdraw its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the advice of the U.S. Food & Drug Administration. The Company also stated that it would reduce spending by nearly 85% and that it would close a Swedish facility, eliminating 40 jobs. When this information was announced, shares of Trinity fell in value.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.